Search results
Added:
2 weeks ago
Source:
Radcliffe CVRM
While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have established cardiorenal benefits in type 2 diabetes, long-term data for their use in patients with type 1 diabetes (T1D) have been scarce. A new large-scale study suggests that initiating GLP-1RA therapy is associated with a lower risk of major adverse cardiovascular and kidney outcomes in this population, without compromising safety…
View more
Roberto Latini
Job title: Head of the Cardiovascular Clinical Pharmacology Laboratory
Author
Maurizio Volterrani
Job title: Head of the Cardiological Rehabilitation Unit
Author
Biykem Bozkurt
Research Area(s) / Expertise:
Author
Stephan Von Haehling
Research Area(s) / Expertise:
Author
Expertise
Prevention & Chronic ConditionsChronic Kidney DiseaseCardiovascular Kidney MetabolicHeart FailureDiabetesHeart Failure Diagnosis and ImagingDemographicHypertensionHeart Failure DevicesAgeMetabolic dysfunction-associated fatty liver disease (MAFLD)Heart Failure ComorbiditiesGenderObesityCardiomyopathiesCardiomyopathies and Cardiac Amyloidosis
Dan Burkhoff
Job title: Director
Author
Jozine ter Maaten
Research Area(s) / Expertise:
Job title: Cardiologist
Author
Medhat K Soliman
Research Area(s) / Expertise:
Job title: Associate Staff Physician, Cleveland Clinic Abu Dhabi
Author
Azmee Mohd Ghazi
Research Area(s) / Expertise:
Author
Expertise
Prevention & Chronic ConditionsChronic Kidney DiseaseCardiovascular Kidney MetabolicHeart FailureDiabetesHeart Failure Diagnosis and ImagingDemographicHypertensionHeart Failure DevicesAgeMetabolic dysfunction-associated fatty liver disease (MAFLD)Heart Failure ComorbiditiesGenderObesityCardiomyopathiesCardiomyopathies and Cardiac Amyloidosis
Marc Ulrich Becher
Job title: Interventional Cardiologist and Heart Failure Specialist
Author